BIMEKIZUMAB EFFICACY &amp; SAFETY VERSUS RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 16-WEEK RESULTS FROM A HEAD-TO-HEAD, MULTICENTRE, RANDOMISED, PHASE 3B STUDY (BE BOLD)

Bimzelx (bimekizumab-bkzx) - UCB

Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim

https://distribution-congress.eular.org/from.storage?image=15rRXWmdOAJ77zPlkD-rQuW1TdPP6_9_oPhziVFB72SHmPqvdNrzJYFBsGPduxgu0

Iain B. McInnes1; Laure Gossec2; Alice B. Gottlieb3; Philip J. Mease4; Akimichi Morita5; Yoshiya Tanaka6; Diamant Thaçi7; Barbara Ink8; Alexander Marten9; Jason Coarse 10; Adam Prickett8; Nadine Goldammer9; Myriam Manente11; Joseph F Merola12

May 5, 2026